Immune Thrombocytopenic Purpura Clinical Trial
Official title:
Assessment of Serum interleukin10 Level in Patients With Immune Thrombocytopenic Purpura at Sohag University Hospital
Autoimmune diseases are characterized by various factors that contribute to a breakdown in self-tolerance, that is, the ability of the immune system to effectively distinguish self from non-self and to refrain from attacking self. Autoimmune diseases include a broad spectrum of disorders, such as idiopathic thrombocytopenic purpura, systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, and inflammatory bowel disease. Although significant progress has been achieved in the development of approaches to the treatment of autoimmune diseases, the etiologies, and pathogenesis of autoimmune diseases remain obscure (Tao et al., 2016) Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by bleeding due to isolated thrombocytopenia with platelet count less than 100 × 109/L (Neunert et al., 2019). ITP is classified based on course of disease into acute (3- <12 months), and chronic (≥12 months) (Provan et al., 2019). ITP usually has a chronic course in adults (Moulis et al., 2017) whereas approximately 8090% of children undergo spontaneous remission within weeks to months of disease onset (Heitink et al., 2018). The main pathogenesis of ITP is the loss of immune tolerance to platelet auto-antigens, which results in increased platelet destruction and impaired thrombopoiesis by autoantibodies and cytotoxic T lymphocytes (CTLs) (Adiua et al., 2017). Among these abnormalities include the increased number of the T helper 1 (Th1) cells (Panitsas et al.,2004). the decreased number or defective suppressive function of regulatory T cells (Tregs) (Yu et al., 2008) , and the
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01255332 -
Helicobacter Pylori Immune Thrombocytopenic Purpura
|
Phase 2 | |
| Completed |
NCT02077192 -
Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)
|
Phase 3 | |
| Completed |
NCT01719692 -
Low-dose Rituximab Regimens in Chinese Adult Patients With Immune Thrombocytopenia
|
N/A | |
| Completed |
NCT01621204 -
A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients
|
Phase 3 | |
| Completed |
NCT01730352 -
Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT01713855 -
Vaccine Response After Rituximab for Chronic, Severe Idiopathic Thrombocytopenic Purpura
|
N/A | |
| Not yet recruiting |
NCT05093257 -
Study of T Cells and Natural Killer Cells Expression in Patients With Immune Thrombocytopenic Purpura
|
||
| Completed |
NCT01390649 -
A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)
|
Phase 4 | |
| Completed |
NCT01672151 -
Efficacy of Rapamycin Therapy With Chronic Immune Thrombocytopenia
|
N/A | |
| Completed |
NCT01439321 -
Outcomes Comparison of Chronic Immune Thrombocytopenic Purpura (ITP) Patients Switched to Eltrombopag and Romiplostim
|
N/A | |
| Completed |
NCT00774202 -
Higher Dose of Rituxan Versus Standard Doses of Rituxan With Cyclophosphamide, Vincristine, and Prednisone in Subjects With Chronic ITP
|
Phase 2/Phase 3 | |
| Completed |
NCT02273960 -
Study to Evaluate Safety and Efficacy in Adult Subjects With ITP
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05585944 -
" Effect of Single-nucleotide Polymorphism of CD40 Gene rs1883832 C/T on the Risk of Immune Thrombocytopenic Purpura "
|
N/A | |
| Recruiting |
NCT03177629 -
H. Pylori Eradication for Moderate ITP
|
Phase 3 | |
| Active, not recruiting |
NCT03395210 -
A Study of Rilzabrutinib in Adult Patients With Immune Thrombocytopenia (ITP)
|
Phase 2 | |
| Completed |
NCT00621894 -
Oral LGD-4665 Versus Placebo in Adults With Immune Thrombocytopenic Purpura (ITP) for 6 Weeks Plus Open Treatment Continuation
|
Phase 2 | |
| Completed |
NCT01652599 -
Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT
|
Phase 2 | |
| Completed |
NCT00426270 -
Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults
|
Phase 3 | |
| Completed |
NCT02085993 -
Study of Patients With ITP Estimating the Proportion Administering Romiplostim Correctly After Receiving Home Administration Training
|
N/A | |
| Completed |
NCT00718692 -
Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)
|
Phase 2 |